![]() | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ponatinib.
|
Richard Lehman
editThere ought to be a way to include this beautiful summary:
Just two small difficulties. This drug is priced at $130,000 per year; and it caused major arterial thrombosis in 9% of patients over a year and a quarter. If you’re cool with cancer drugs that nobody can afford and that have devastating harms which only come to light after fast-track licensing, then that’s wonderful. It’s the new paradigm. http://blogs.bmj.com/bmj/2013/11/11/richard-lehmans-journal-review-11-november-2013/ --Nbauman (talk) 09:17, 24 November 2013 (UTC)